Clear Cut Medical Ltd., which is developing a compact MRI device for assisting breast cancer surgery, has raised NIS 2.8 million from new and current investors. The company’s MRI can detect the surgical margins during the procedure to ensure excision of the entire tumor. Clear Cut Medical is a portfolio of Ashkelon Technological Industries (ATI), a subsidiary of Gefen Biomed Investments Ltd. (TASE: GEFEN). Gefen’s share in the company fell from 29.8% to 24% following the financing.
